Differential matrix metalloproteinase levels in adenocarcinoma and squamous cell carcinoma of the lung

被引:31
作者
Shah, Sonam A.
Spinale, Francis G.
Ikonomidis, John S.
Stroud, Robert E.
Chang, Eileen I.
Reed, Carolyn E. [1 ]
机构
[1] MUSC, Dept Surg, Div Cardiothorac Surg, Charleston, SC 29425 USA
关键词
TISSUE INHIBITOR; PLASMA MATRIX-METALLOPROTEINASE-9; VENTRICULAR MYOCARDIUM; MESSENGER-RNA; PHASE-III; CANCER; EXPRESSION; SURVIVAL; MMP-9; PROGNOSIS;
D O I
10.1016/j.jtcvs.2009.12.016
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: The matrix metalloproteinases (MMPs) have been implicated in the aggressive course of non-small cell lung cancer (NSCLC). However, there are a large number of MMP subtypes with diverse proteolytic substrates and different induction pathways. This study tested the hypothesis that a differential MMP profile would exist between NSCLC and normal lung and that MMP patterns would differ between NSCLC histologic types. Methods: NSCLC samples and remote normal samples were obtained from patients with stage I or II NSCLC with either squamous cell (n = 22) or adenocarcinoma (n = 19) histologic characteristics. Absolute concentrations for each of the MMP subclasses were determined by a calibrated and validated multiplex suspension array: collagenases (MMP-1, -8, and -13), gelatinases (MMP-2 and -9), lysins (MMP-2 and -7), and elastase (MMP-12). Results: Overall, MMP levels were significantly increased in NSCLC compared with normal. For example, MMP-1 and MMP-7 increased by approximately 10-fold in NSCLC (P < .05). Moreover, a different MMP portfolio was observed between NSCLC histologic types. For example MMP-1, -8, -9, and -12 increased by more than 4-fold in squamous cell versus adenocarcinoma (P < .05). In those patients who had recurrence within 3 years of resection, 3-fold higher levels of MMP-8 and -9 were observed (P < .05). Conclusion: Increased levels of a number of MMP types occur with NSCLC, but the MMP profile was distinctly different between histologic types and in those patients with recurrence. These different MMP profiles may be important in the mechanistic basis for the natural history of different NSCLC types, as well as identifying potential prognostic and therapeutic targets. (J Thorac Cardiovasc Surg 2010; 139: 984-90)
引用
收藏
页码:984 / 990
页数:7
相关论文
共 39 条
[1]   Upregulation of the tissue inhibitor of metalloproteinase-1 protein is associated with progression of human non-small-cell lung cancer [J].
Aljada, IS ;
Ramnath, N ;
Donohue, K ;
Harvey, S ;
Brooks, JJ ;
Wiseman, SM ;
Khoury, T ;
Loewen, G ;
Slocum, HK ;
Anderson, TM ;
Bepler, G ;
Tan, DF .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (16) :3218-3229
[2]   Metalloproteinase inhibitors: biological actions and therapeutic opportunities [J].
Baker, AH ;
Edwards, DR ;
Murphy, G .
JOURNAL OF CELL SCIENCE, 2002, 115 (19) :3719-3727
[3]   Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer [J].
Bissett, D ;
O'Byrne, KJ ;
von Pawel, J ;
Gatzemeier, U ;
Price, A ;
Nicolson, M ;
Mercier, R ;
Mazabel, E ;
Penning, C ;
Zhang, MH ;
Collier, MA ;
Shepherd, FA .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (04) :842-849
[4]   Urokinase receptor, MMP-1 and MMP-9 are markers to differentiate prognosis, adenoma and carcinoma in thyroid malignancies [J].
Buergy, Daniel ;
Weber, Theresia ;
Maurer, Gabriele D. ;
Mudduluru, Giridhar ;
Medved, Fabian ;
Leupold, Joerg H. ;
Brauckhoff, Michael ;
Post, Stefan ;
Dralle, Henning ;
Allgayer, Heike .
INTERNATIONAL JOURNAL OF CANCER, 2009, 125 (04) :894-901
[5]   The regulation of matrix metalloproteinases and their inhibitors [J].
Clark, Ian A. ;
Swingler, Tracey E. ;
Sampieri, Clara L. ;
Edwards, Dylan R. .
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2008, 40 (6-7) :1362-1378
[6]   Cancer therapy - Matrix metalloproteinase inhibitors and cancer: Trials and tribulations [J].
Coussens, LM ;
Fingleton, B ;
Matrisian, LM .
SCIENCE, 2002, 295 (5564) :2387-2392
[7]   Trafficking of the membrane type-1 matrix metalloproteinase in ischemia and reperfusion - Relation to interstitial membrane type-1 matrix metalloproteinase activity [J].
Deschamps, AM ;
Yarbrough, WM ;
Squires, CE ;
Allen, RA ;
McClister, DM ;
Dowdy, KB ;
McLean, JE ;
Mingoia, JT ;
Sample, JA ;
Mukherjee, R ;
Spinale, FG .
CIRCULATION, 2005, 111 (09) :1166-1174
[8]   New functions for the matrix metalloproteinases in cancer progression [J].
Egeblad, M ;
Werb, Z .
NATURE REVIEWS CANCER, 2002, 2 (03) :161-174
[9]   Endothelin-A Receptor Inhibition After Cardiopulmonary Bypass: Cytokines and Receptor Activation [J].
Ford, Rachael L. ;
Mains, Ira M. ;
Hilton, Ebony J. ;
Reeves, Scott T. ;
Stroud, Robert E. ;
Crawford, Fred A., Jr. ;
Ikonomidis, John S. ;
Spinale, Francis G. .
ANNALS OF THORACIC SURGERY, 2008, 86 (05) :1576-1583
[10]  
Gentner B, 2009, ANTICANCER RES, V29, P67